Literature DB >> 19565928

Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas.

Mateusz Opyrchal1, Ileana Aderca, Evanthia Galanis.   

Abstract

Despite many advances in cancer therapy, metastatic disease continues to be incurable in the majority of cancer patients. There is an need for more efficient and less toxic treatments in this setting. Oncolytic virotherapy represents a novel promising direction in the treatment of cancer. Based on preclinical and clinical data, combination with standard chemotherapy has the potential to further increase the antitumor activity of oncolytic virotherapy in a synergistic manner. We present the design of a phase I clinical trial combining intratumoral injections of the oncolytic adenovirus ONYX-015 with systemic chemotherapy in patients with advanced sarcomas.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19565928      PMCID： PMC3180922          DOI： 10.1007/978-1-59745-561-9_35

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  21 in total

1.  a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.

Authors:  F R Khuri; J Nemunaitis; I Ganly; J Arseneau; I F Tannock; L Romel; M Gore; J Ironside; R H MacDougall; C Heise; B Randlev; A M Gillenwater; P Bruso; S B Kaye; W K Hong; D H Kirn
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

2.  Inhibition of simian virus 40 DNA replication in vitro by poly(ADP-ribosyl)ated diadenosine tetraphosphate.

Authors:  J C Baker; S T Smale; R Tjian; B N Ames
Journal:  J Biol Chem       Date:  1987-11-05       Impact factor: 5.157

3.  Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.

Authors:  Tony Reid; Eva Galanis; James Abbruzzese; Dan Sze; Lawrence M Wein; James Andrews; Britta Randlev; Carla Heise; Margaret Uprichard; Michael Hatfield; Larry Rome; Joseph Rubin; David Kirn
Journal:  Cancer Res       Date:  2002-11-01       Impact factor: 12.701

4.  A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.

Authors:  I Ganly; D Kirn; G Eckhardt; G I Rodriguez; D S Soutar; R Otto; A G Robertson; O Park; M L Gulley; C Heise; D D Von Hoff; S B Kaye; S G Eckhardt
Journal:  Clin Cancer Res       Date:  2000-03       Impact factor: 12.531

5.  Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.

Authors:  J Nemunaitis; I Ganly; F Khuri; J Arseneau; J Kuhn; T McCarty; S Landers; P Maples; L Romel; B Randlev; T Reid; S Kaye; D Kirn
Journal:  Cancer Res       Date:  2000-11-15       Impact factor: 12.701

Review 6.  Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

Authors:  D Kirn
Journal:  Gene Ther       Date:  2001-01       Impact factor: 5.250

7.  Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity.

Authors:  J Nemunaitis; C Cunningham; A Buchanan; A Blackburn; G Edelman; P Maples; G Netto; A Tong; B Randlev; S Olson; D Kirn
Journal:  Gene Ther       Date:  2001-05       Impact factor: 5.250

8.  Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer.

Authors:  P A Vasey; L N Shulman; S Campos; J Davis; M Gore; S Johnston; D H Kirn; V O'Neill; N Siddiqui; M V Seiden; S B Kaye
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

9.  A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.

Authors:  J Randolph Hecht; Rudolph Bedford; James L Abbruzzese; Sandeep Lahoti; Tony R Reid; Roy M Soetikno; David H Kirn; Scott M Freeman
Journal:  Clin Cancer Res       Date:  2003-02       Impact factor: 12.531

10.  Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer.

Authors:  Oday Hamid; Mary L Varterasian; Scott Wadler; J Randolph Hecht; Al Benson; Evanthia Galanis; Margaret Uprichard; Charles Omer; Paul Bycott; Robert C Hackman; Anthony F Shields
Journal:  J Clin Oncol       Date:  2003-04-15       Impact factor: 44.544
View more
  16 in total

1.  A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases.

Authors:  Kristopher J Kimball; Meredith A Preuss; Mack N Barnes; Minghui Wang; Gene P Siegal; Wen Wan; Huichien Kuo; Souheil Saddekni; Cecil R Stockard; William E Grizzle; Raymond D Harris; Rosemarie Aurigemma; David T Curiel; Ronald D Alvarez
Journal:  Clin Cancer Res       Date:  2010-10-26       Impact factor: 12.531

2.  Inhibitory effect of Survivin promoter-regulated oncolytic adenovirus carrying P53 gene against gallbladder cancer.

Authors:  Chen Liu; Bin Sun; Ni An; Weifeng Tan; Lu Cao; Xiangji Luo; Yong Yu; Feiling Feng; Bin Li; Mengchao Wu; Changqing Su; Xiaoqing Jiang
Journal:  Mol Oncol       Date:  2011-10-19       Impact factor: 6.603

Review 3.  Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.

Authors:  Sonia Tusell Wennier; Jia Liu; Grant McFadden
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

4.  Bioengineered viral vectors for targeting and killing prostate cancer cells.

Authors:  Kai-xin Zhang; William Jia; Paul S Rennie
Journal:  Bioeng Bugs       Date:  2010-01-04

5.  Concurrent chemotherapy inhibits herpes simplex virus-1 replication and oncolysis.

Authors:  Y Kulu; H Kawasaki; J M Donahue; H Kasuya; J C Cusack; E W Choi; D K Kuruppu; B C Fuchs; K K Tanabe
Journal:  Cancer Gene Ther       Date:  2013-01-25       Impact factor: 5.987

6.  Gene transfer into rat brain using adenoviral vectors.

Authors:  Mariana Puntel; Kurt M Kroeger; Nicholas S R Sanderson; Clare E Thomas; Maria G Castro; Pedro R Lowenstein
Journal:  Curr Protoc Neurosci       Date:  2010-01

7.  Anti-tumor activity of a miR-199-dependent oncolytic adenovirus.

Authors:  Elisa Callegari; Bahaeldin K Elamin; Lucilla D'Abundo; Simonetta Falzoni; Giovanna Donvito; Farzaneh Moshiri; Maddalena Milazzo; Giuseppe Altavilla; Luciano Giacomelli; Francesca Fornari; Akseli Hemminki; Francesco Di Virgilio; Laura Gramantieri; Massimo Negrini; Silvia Sabbioni
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240

8.  A vesicular stomatitis virus glycoprotein epitope-incorporated oncolytic adenovirus overcomes CAR-dependency and shows markedly enhanced cancer cell killing and suppression of tumor growth.

Authors:  A-Rum Yoon; Jinwoo Hong; Chae-Ok Yun
Journal:  Oncotarget       Date:  2015-10-27

Review 9.  Role of microRNAs in hepatocellular carcinoma: a clinical perspective.

Authors:  Elisa Callegari; Bahaeldin K Elamin; Silvia Sabbioni; Laura Gramantieri; Massimo Negrini
Journal:  Onco Targets Ther       Date:  2013-09-02       Impact factor: 4.147

10.  Enhanced susceptibility of B lymphoma cells to measles virus by Epstein-Barr virus type III latency that upregulates CD150/signaling lymphocytic activation molecule.

Authors:  Satoshi Takeda; Daiki Kanbayashi; Takako Kurata; Hironori Yoshiyama; Jun Komano
Journal:  Cancer Sci       Date:  2014-01-12       Impact factor: 6.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.